National Institute for Health and Care Excellence

EGFR‑TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer

Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer: equality impact assessment - guidance Epidermal ...
National Institute for Health and Care Excellence

EGFR‑TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer

The systematic review was carried out to identify evidence on the technical performance and clinical effectiveness of the different options available to detect epidermal growth factor receptor ...
ascopubs.org

EGFR mutation testing trends for patients with metastatic, non-squamous non-small cell lung cancer (non-SQ NSCLC) in Queensland, Australia from 2014-2021.

Association between patient tumour characteristics and five-year survival in Nigerian patients with breast cancer.
Yahoo Finance

Lunit to Present AI Study on EGFR Mutation Prediction in NSCLC at AACR 2025 in Collaboration with AstraZeneca

AI-powered model predicts EGFR mutations from H&E-stained slides, demonstrating robust performance across diverse clinical settings and helping overcome barriers to molecular testing in NSCLC SEOUL, ...
Healio

VIDEO: Evolution of biomarker testing in EGFR-mutated lung cancer

Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify editor@healio.com if there are concerns ...
PharmiWeb

Biocartis Announces IVDR Class C CDx Certification of the Idylla™ EGFR Mutation Test

Mechelen, Belgium, 02 June 2025 – Biocartis NV (“Biocartis”), an innovative molecular diagnostics company, is pleased to announce that its Idylla™ EGFR Mutation Test has received the European Union ...
ascopubs.org

A comparison of real-world incidence of EGFR exon 20 insertion mutations among patients with NSCLC in five Asian markets, stratified by testing methodology.

Immunotherapy in stage IV non-small cell lung cancer according to racial characteristics and community of residence. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract ...
Hosted on MSN

Biocartis’ EGFR Mutation Test gains IVDR Class C CDx certification

Biocartis’ Idylla EGFR Mutation Test has secured the EU Technical Documentation Assessment and Quality Management System certificate, making it the first Idylla Test to achieve Class C companion ...